Agilysys is a provider of hospitality software. The company delivers technology solutions for gaming, hotels, resorts and cruise, corporate foodservice management, restaurants, universities, stadia and healthcare. The company provides solutions in the industry, including point of sales, property management, inventory and procurement, payments, and related applications, to manage the entire guest journey. The company is a developer and marketer of software enabled solutions and services to the hospitality industry, including software solutions fully integrated with third party hardware and operating systems; support, maintenance and subscription services; and other services.

Amplify Energy is a holding company. Through its wholly-owned subsidiary, Midstates Petroleum Company LLC, the company is an independent exploration and production company focused on the application of drilling, completion and production operations techniques in oil and liquids basins in the onshore U.S. The company's operations are focused on exploration and production activities in the Mississippian Lime. The company's Mississippian Lime assets are located in Oklahoma and target the Mississippian Lime formation.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating disease through the inhibition of the complement system, which is a component of the immune system, at the level of C3, the central protein in the complement cascade. The company's clinical program targets C3 with Phase 3 clinical trials of its main product candidate, APL-2, in multiple indications. APL-2 has the potential to be a treatment that address the limitations of existing treatment options or provide a treatment option. The company is also conducting a Phase 2 trial of APL-2 in glomerular diseases, including C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy and lupus nephritis.

bluebird bio is a biotechnology company engaged in researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. The company has built a product platform with a range of therapeutic potential in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. The company is developing LentiGlobin gene therapy for sickle cell disease; Lenti-D gene therapy for cerebral adrenoleukodystrophy; and in collaboration with Bristol-Myers Squibb, the company is developing bb2121 (idecabtagene vicleucel) and bb21217 product candidates as treatments for multiple myeloma.

Celcuity is a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. This enables physicians to select therapeutic that matches and inhibits a patient's cellular dysfunction.

Clearfield designs, manufactures and distributes fiber protection, fiber management and fiber delivery solutions. The company's products include: FieldSmart?, which provides a design from the inside plant of the telco's central office or cable television's head-end, all the way through the outside plant to the access network to within the home or business; WaveSmart? optical components, which are integrated for signal coupling, splitting, termination, multiplexing, demultiplexing and attenuation for an integration within the company's fiber management platform; and ODC outdoor active cabinet product line, which features a line of cabinets equipped with specific active electronics configurations.

EVI Industries, through its subsidiaries, is a distributor, and provides advisory and technical services; provides its customers planning, designing, and consulting services related to their commercial laundry operations; and sells and/or leases its customers commercial laundry equipment specializing in washing, drying, finishing, material handling, water heating, power generation, and water reuse applications. The company's customers include retail, commercial, industrial, institutional, and government customers. The company also sells replacement parts and accessories for the products it distributes. The company also provides installation and maintenance services to its customers.

Harrow Health focuses on the development, production and sale of medications. The company mainly focuses on its ImprimisRx business, which is an ophthalmology pharmaceutical compounding business, and Park Compounding, Inc., which is a pharmacy focused primarily on health and wellness related, customizable pharmaceutical compounding. The company's other subsidiaries include: Eton Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products utilizing the U.S. Food and Drug Administration 505(b)(2) regulatory pathway; and Surface Pharmaceuticals, Inc., a pharmaceutical company focused on development and commercialization of therapeutics for ocular surface diseases.

MaxCyte is a developer and supplier of proprietary electroporation technology to biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery and development and biomanufacturing. Co. licenses its instruments and technology and sells its consumables to developers of cell therapies. Co. also sells and licenses its instruments and sells its consumables to pharmaceutical and biotechnology companies for use in drug discovery and development and biomanufacturing. Co. is also developing CARMA, a CAR-based cell therapy targeting solid and liquid cancers, through internal research and collaborations with academic institutions.

Neurocrine Biosciences is a commercial-stage biopharmaceutical company focused on discovering and developing treatments for patients with neurological, endocrine and psychiatric disorders. The company is primarily focused on the commercialization of INGREZZA? (valbenazine) in the United States. The company's late-stage pipeline includes opicapone as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients, elagolix for the treatment of heavy menstrual bleeding associated with uterine fibroids in women, valbenazine for the treatment of chorea in adult patients with Huntington's disease and NBIb-1817 (VY-AADC) for the treatment of Parkinson's disease patients.

REGENXBIO is a clinical-stage biotechnology company. The company's product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; and RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is for the treatment of homozygous familial hypercholesterolemia.

Revance Therapeutics is a clinical-stage biotechnology company focused on the development, manufacturing and commercialization of neuromodulators for multiple aesthetic and therapeutic indications. The company focuses on developing daxibotulinumtoxinA, its purified botulinum toxin Type A, for a spectrum of aesthetic and therapeutic indications, including facial wrinkles, muscle disorders, and chronic migraine. The company's main drug candidate is DaxibotulinumtoxinA for Injection. The company also is developing a topically applied neuromodulator for aesthetic and therapeutic indications, DaxibotulinumtoxinA Topical, and have a collaboration and license agreement to develop and commercialize a biosimilar to BOTOX?.

Rocket Pharmaceuticals is a clinical-stage, multi-platform biotechnology company focused on the development of gene therapies for rare and devastating pediatric diseases. The company has the following inical-stage ex vivo lentiviral vector programs enrolling patients in the U.S. and European Union for Fanconi Anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I, a genetic disorder that causes the immune system to malfunction and Pyruvate Kinase Deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

Seres Therapeutics is a microbiome therapeutics platform company developing a class of biological drugs, which it refers to as Ecobiotic? microbiome therapeutics. SER-287 is being developed to treat ulcerative colitis, or UC. SER-109 is designed to reduce recurrences of Clostridium difficile infection, or CDI, a debilitating infection of the colon, in patients who have received antibiotic therapy for recurrent CDI by treating the dysbiosis of the colonic microbiome. In addition, using its microbiome therapeutics platform, the company is developing product candidates to treat diseases including SER-301, a rationally designed, fermented UC candidate, and SER-401, a microbiome therapeutic candidate.

Transcat is a provider of calibration and laboratory instrument services and a distributor of grade test, measurement and control instrumentation. The company provides services and products to the life science industry, including pharmaceutical, biotechnology, medical device and other Food and Drug Administration-regulated businesses. The company's segments are: Service, which provides calibration, repair, inspection, analytical qualifications, preventative maintenance, consulting and other related services, of which are processed via its asset management system, CalTrak? and its online customer portal, C3?; and Distribution, which sells and rents national and proprietary brand instruments to customers.